NCT06478589 Patient Priorities for Survivorship Care in Older Breast Cancer Survivors
| NCT ID | NCT06478589 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | The University of Texas Health Science Center, Houston |
| Condition | Breast Cancer Survivorship |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-01-02 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 120 participants in total. It began in 2025-01-02 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this study is to adapt the Patient Priorities Care (PPC) framework to breast cancer survivorship via a user-centered approach, through an iterative process in which patients and their physicians help to refine and modify the intervention. A second objective is to evaluate the feasibility and effectiveness of the adapted PPC framework in breast cancer survivorship for older adults.
Eligibility Criteria
Inclusion Criteria: * able to write and speak English * Stage DCIS/I/II/III breast cancer diagnosis * 3 months from active cancer therapy (including first or second-line treatment chemotherapy, radiation and/or surgery, or multimodal treatment) up to 10 years since completing treatment * ≥3 documented comorbidities by chart review, or taking ≥10 medications, have ≥ 1 hospitalization over the past year, ≥ 2 emergency department visits over the past year, seen by \> 2 specialists over the past year * able to provide consent Exclusion Criteria: * currently on active cancer therapy (including first or second-line treatment chemotherapy, radiation and/or surgery, or multimodal treatment)
Contact & Investigator
Dana E. Giza, MD
PRINCIPAL INVESTIGATOR
The University of Texas Health Science Center, Houston
Frequently Asked Questions
Who can join the NCT06478589 clinical trial?
This trial is open to female participants only, aged 65 Years or older, up to 100 Years, studying Breast Cancer Survivorship. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06478589 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06478589 currently recruiting?
Yes, NCT06478589 is actively recruiting participants. Contact the research team at Dana.E.Giza@uth.tmc.edu for enrollment information.
Where is the NCT06478589 trial being conducted?
This trial is being conducted at Bellaire, United States, Houston, United States, Houston, United States.
Who is sponsoring the NCT06478589 clinical trial?
NCT06478589 is sponsored by The University of Texas Health Science Center, Houston. The principal investigator is Dana E. Giza, MD at The University of Texas Health Science Center, Houston. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.